Prometheus Biosciences Inc. (RXDX) – Globe Newswire
-
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
-
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
-
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
-
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
-
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
-
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
-
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
-
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences to Participate at November Healthcare Conferences
-
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
-
Prometheus Biosciences to Participate at September Healthcare Conferences
-
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
-
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
-
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
-
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
-
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
-
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
-
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
-
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
-
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
-
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
-
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
-
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
-
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
-
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
-
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
-
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
-
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences to Present at Upcoming Investor Conferences
-
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
-
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
-
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
-
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
-
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform
-
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
-
Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board
-
Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board
-
Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
Back to RXDX Stock Lookup
